These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 3546575)
21. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Ogunniyi AD; LeMessurier KS; Graham RM; Watt JM; Briles DE; Stroeher UH; Paton JC Infect Immun; 2007 Apr; 75(4):1843-51. PubMed ID: 17261599 [TBL] [Abstract][Full Text] [Related]
22. Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Miyaji EN; Ferreira DM; Lopes AP; Brandileone MC; Dias WO; Leite LC Infect Immun; 2002 Sep; 70(9):5086-90. PubMed ID: 12183557 [TBL] [Abstract][Full Text] [Related]
23. Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Waltman WD; McDaniel LS; Gray BM; Briles DE Microb Pathog; 1990 Jan; 8(1):61-9. PubMed ID: 2333033 [TBL] [Abstract][Full Text] [Related]
24. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Berry AM; Yother J; Briles DE; Hansman D; Paton JC Infect Immun; 1989 Jul; 57(7):2037-42. PubMed ID: 2731982 [TBL] [Abstract][Full Text] [Related]
25. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Ren B; Szalai AJ; Thomas O; Hollingshead SK; Briles DE Infect Immun; 2003 Jan; 71(1):75-85. PubMed ID: 12496151 [TBL] [Abstract][Full Text] [Related]
26. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. Miyaji EN; Dias WO; Tanizaki MM; Leite LC FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760 [TBL] [Abstract][Full Text] [Related]
27. Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B Streptococcus pneumoniae. Crain MJ; Turner JS; Robinson DA; Coffey TJ; Brooks-Walter A; McDaniel LS; Briles DE Microb Pathog; 1996 Oct; 21(4):265-75. PubMed ID: 8905615 [TBL] [Abstract][Full Text] [Related]
28. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026 [TBL] [Abstract][Full Text] [Related]
29. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Brooks-Walter A; Briles DE; Hollingshead SK Infect Immun; 1999 Dec; 67(12):6533-42. PubMed ID: 10569772 [TBL] [Abstract][Full Text] [Related]
30. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines. Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840 [TBL] [Abstract][Full Text] [Related]
31. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869 [TBL] [Abstract][Full Text] [Related]
32. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Ren B; Szalai AJ; Hollingshead SK; Briles DE Infect Immun; 2004 Jan; 72(1):114-22. PubMed ID: 14688088 [TBL] [Abstract][Full Text] [Related]
33. The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding protein that is essential for virulence. Holmes AR; McNab R; Millsap KW; Rohde M; Hammerschmidt S; Mawdsley JL; Jenkinson HF Mol Microbiol; 2001 Sep; 41(6):1395-408. PubMed ID: 11580843 [TBL] [Abstract][Full Text] [Related]
34. Epitope mapping of pneumococcal surface protein A of strain Rx1 using monoclonal antibodies and molecular structure modelling. Kolberg J; Aase A; Rødal G; Littlejohn JE; Jedrzejas MJ FEMS Immunol Med Microbiol; 2003 Dec; 39(3):265-73. PubMed ID: 14642312 [TBL] [Abstract][Full Text] [Related]
36. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242 [TBL] [Abstract][Full Text] [Related]
37. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice. Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043 [TBL] [Abstract][Full Text] [Related]
38. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Quin LR; Moore QC; McDaniel LS Infect Immun; 2007 Apr; 75(4):2067-70. PubMed ID: 17220305 [TBL] [Abstract][Full Text] [Related]
39. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA). Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550 [TBL] [Abstract][Full Text] [Related]
40. Characterization of selected strains of pneumococcal surface protein A. Jedrzejas MJ; Lamani E; Becker RS J Biol Chem; 2001 Aug; 276(35):33121-8. PubMed ID: 11413137 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]